Derivation Web

source_54c37f6f76e14b11

by researka:v2 · 2026-06-24 05:56:17.277633+04:00

# Hypothesis-Generating Brief: Statins longevity — full paper
## Abstract

Evidence-honesty note: 32/53 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 50/53 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

Statins are among the most widely prescribed drug classes, yet their effects on human longevity, geroscience-relevant functional decline, and disease-specific survival remain contested, with the question intensifying as multimorbid older adults are increasingly considered for initiation or deprescribing (Aebi 2025; Vordenberg 2026).

Functional surrogates in older adults carry prognostic weight well beyond lipid numbers — for example, gait speed near 0.8 m/s has been tied to frailty risk (Studenski 2011), and an annual decline of 0.05 m/s is typical in aging cohorts (Bohannon 1997) — making statin effects on physical function a longevity-relevant, not merely symptomatic, question.

Additional corpus sources included animal/preclinical evidence; we conducted an AI-assisted structured evidence synthesis across 53 curated references, with every claim traced to a numbered source and tensions between mechanistic, observational, and randomized evidence explicitly logged rather than smoothed over (Pintea 2026; Lv 2025).

Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

## Introduction

This synthesis evaluates evidence on Statins longevity across 53 included source papers and 3220 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, indirect interventional hard-endpoint evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 3 direct clinical sources, 49 adjacent clinical sources, and 1 mechanistic or model-system source. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The thesis is: Across 53 curated reference papers, the evidence base for Statins shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Null findings dominate: contextual other, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Statins anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

## Background

Additional corpus sources included animal/preclinical evidence; the background evidence for Statins longevity is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Qian 2026, Fernando 2025, Zheng 2025 are interpreted separately from mechanistic studies such as Lv 2025, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the contextual adjacent evidence, longevity, immune and inflammation outcome classes; null signals around the contextual adjacent evidence, safety and comorbidity, longevity outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-statins_longevity-v06-DAILY-2026-06-24T01-24-41Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-24.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `statins longevity AND aging AND human`
- `statins longevity AND older adults`
- `statins longevity AND randomized controlled trial`
- `statins AND aging AND human`
- `statins AND older adults`
- `statins AND randomized controlled trial`
- `atorvastatin AND aging AND human`
- `atorvastatin AND older adults`
- `atorvastatin AND randomized controlled trial`
- `rosuvastatin AND aging AND human`

### Eligibility criteria
- Sources whose primary content addresses statins longevity.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 189 records in the receipt-candidate union, 69 were classified as source candidates and 53 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| Receipt candidate union | 189 |
| Classified source candidates | 69 |
| No extractable claims | 14 |
| None-only claim binding | 3 |
| Mixed partial-or-none claim-binding candidates | 70 |
| Partial-only claim-binding candidates | 18 |
| Strict high-confidence sources | 15 |
| Admitted final sources | 53 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, immune and inflammation, longevity, mortality and survival, muscle function, safety, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Results
| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Contextual Adjacent Evidence | n=29; claims=1274 | no extracted directional signal in 22/29 sources | 1 direct; 12 indirect; 3 protocol; 13 review | limited corpus depth in this outcome class |
| Longevity | n=7; claims=593 | unclear signal in 2/7 sources | 2 indirect; 5 review | limited corpus depth in this outcome class |
| Safety and Comorbidity | n=5; claims=321 | no extracted directional signal in 3/5 sources | 1 direct; 4 review | limited corpus depth in this outcome class |
| Cardiometabolic | n=3; claims=600 | unclear signal in 2/3 sources | 2 indirect; 1 review | limited corpus depth in this outcome class |
| Dosing and Pharmacokinetics | n=2; claims=130 | unclear signal in 1/2 sources | 1 direct; 1 review | limited corpus depth in this outcome class |
| Immune and Inflammation | n=2; claims=139 | positive signal in 1/2 sources | 1 indirect; 1 review | limited corpus depth in this outcome class |
| Mortality and Survival | n=2; claims=66 | unclear signal in 1/2 sources | 1 indirect; 1 review | limited corpus depth in this outcome class |
| Muscle Function | n=1; claims=12 | no extracted directional signal in 1/1 sources | 1 protocol | single-source slice; hypothesis-generating |
| Safety | n=1; claims=27 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |
| Skeletal, Fracture, and Bone | n=1; claims=58 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.



### Results Summary

- Contextual Adjacent Evidence: n=29; claims=1274; no extracted directional signal in 22/29 sources | directness: 1 direct; 12 indirect; 13 review; 3 protocol; main limitation: directionally heterogeneous.
- Longevity: n=7; claims=593; mixed signal in 2/7 sources | directness: 2 indirect; 5 review; main limitation: no direct clinical anchor.
- Safety and Comorbidity: n=5; claims=321; no extracted directional signal in 3/5 sources | directness: 1 direct; 4 review; main limitation: directionally heterogeneous.
- Cardiometabolic: n=3; claims=600; mixed signal in 2/3 sources | directness: 2 indirect; 1 review; main limitation: no direct clinical anchor.
- Dosing and Pharmacokinetics: n=2; claims=130; no extracted directional signal in 1/2 sources | directness: 1 direct; 1 review; main limitation: directionally heterogeneous.
- Immune and Inflammation: n=2; claims=139; benefit signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

Three sources populate the cardiometabolic outcome class, each interrogating a different facet of statin exposure rather than mortality per se. Spiegeleer 2025 examined statin use in older adults through an observational cohort lens, with gait speed reserve (GSR) as the functional cardiometabolic readout (Spiegeleer 2025). No source in this class directly tested hard longevity endpoints such as all-cause mortality or healthy lifespan.

Quantitative signals across the class are heterogeneous. These source-traced numerics populate the evidence synthesis and indicate that adverse-event, functional, and lipid endpoints each carry statistically detectable variation without converging on a unified cardiometabolic direction.

Mechanistically, the cardiometabolic class triangulates three distinct causal substrates. In a clinical observational cohort, Alqasrawi 2025 frames statin tolerability as a pharmacogenomic problem, with adverse-event incidence modulated by SLCO1B1- and CYP3A4-related variants (Alqasrawi 2025). Mechanistic human data from Spiegeleer 2025 implicate concomitant-medication burden, suggesting that gait-speed decrements in statin users may reflect polypharmacy rather than statin monotherapy (Spiegeleer 2025). Preclinical and clinical lipid-pathway evidence in Masood 2026 positions PPAR-α agonism as an alternative triglyceride-lowering route, indirectly testing whether the cardiometabolic benefits traditionally attributed to statins can be recapitulated by a mechanistically adjacent agent (Masood 2026). Together, these substrates frame cardiometabolic change as a function of lipid handling, drug clearance genetics, and concomitant exposures rather than a single longevity pathway.

Within-corpus tensions surface chiefly through disagreement over whether statin exposure is harmful, neutral, or beneficial on cardiometabolic surrogates. Alqasrawi 2025 reports mixed adverse-event signals with effect direction marked unclear and individual p-values spanning P = 0.0730 to P < 0.0001, indicating that some adverse outcomes track robustly with statin exposure while others do not (Alqasrawi 2025). The integrating thesis that Statins presents a context-dependent profile is consistent with these source-level disagreements: positive, null, and adverse signals coexist across the cardiometabolic class, and no single source resolves the direction of effect on longevity-relevant cardiometabolic endpoints.

### Contextual Adjacent Evidence Outcomes

The contextual other evidence class is the dominant outcome category in the corpus and aggregates 53 curated reference papers spanning Alzheimer's disease, lipid variability, migraine, cirrhotic portal hypertension, thoracic aortic aneurysm growth, colorectal cancer prognosis, traumatic brain injury recovery, schizophrenia, pancreatic ductal adenocarcinoma, and LDL-C pharmacogenetics. In a clinical RCT design, Aebi 2025 frames the STREAM non-inferiority trial of statin discontinuation in multimorbid older adults without cardiovascular disease, with a primary composite of major CV events and a protocol-level signal at P = 0.04. A mechanistic/biomarker RCT is reported by Zheng 2025, where the EPISODE trial evaluates PCSK9 inhibition on a background of stable statin therapy (rosuvastatin or atorvastatin) for at least 4 weeks in calcific aortic valve stenosis.

Quantitative findings across contextual other are heterogeneous and partly contradictory. Makhlouf 2025 reported positive signals for migraine with HMGCR-expression MR ORs and P < 0.001 for several comparisons.

Mechanistically, the contextual other endpoints map onto distinct pathways rather than a shared longevity axis: lipoprotein flux and LDL-C variability (Lee 2025; Khalil 2025; Xiang 2025; Asiimwe 2026), pleiotropic inflammation and neutrophil/lymphocyte-derived indices (Demirci 2025; Kakkar 2026), endothelial and angiogenic balance (Khalili 2025; Kakkar 2026), hepatic sinusoidal and portal pressure hemodynamics (MORENO 2026), thrombo-inflammatory proteomic signatures after acute myocardial infarction (Schmidt 2026), tumor lipid metabolism (Lv 2025; Pintea 2026; Li 2026), and neuronal lipid raft / HMGCR-related signaling (Makhlouf 2025; Veillette 2025; Saishoji 2025). These human-readable labels — clinical RCT, mechanistic human studies, preclinical data — keep the substrate-to-outcome mapping transparent.

Additional corpus sources included animal/preclinical evidence; within-corpus tensions are dense in this outcome class. Makhlouf 2025 reports positive effect directions on several contextual other endpoints, whereas Du 2025, Veillette 2025, Xiang 2025, Aebi 2025, Markan 2025, Kolimas 2025, Khalili 2025, Lee 2025, Khalil 2025, Saishoji 2025, Park 2025, Takechi 2025, Lv 2025, Albawaneh 2025, Li 2026, Ali 2026, Schmidt 2026, Vordenberg 2026, Kakkar 2026, Pintea 2026, and Voit 2026 each record null effects on overlapping contextual outcomes — a partial conflict pattern that the cross-study disagreement map flags at severity 4 for each pair. Across the corpus, the contextual other evidence is positive in selected oncology, dementia, and lipid-combination signals but null or mixed across the majority of cardiovascular, hepatic, neurological, and pharmacogenetic endpoints.

### Dosing and Pharmacokinetics Outcomes

Within the curated corpus, the dosing pharmacokinetics outcome class is represented by one direct mechanistic randomized trial and one systematic review with meta-analysis. Shahid 2025 is a Cochrane-methodology systematic review and meta-analysis of randomized controlled trials evaluating high-dose statins for the prevention of recurrent ischemic stroke, with a comprehensive search of PubMed, Embase, the Cochrane Library, and clinicaltrials. The two studies differ fundamentally in design — a direct single-trial biomarker evaluation versus a pooled review-level synthesis — and this design asymmetry is preserved rather than collapsed in the synthesis.

Per-study endpoint p-value tuples are catalogued in the evidence synthesis (Per-Study Endpoint Evidence); the prose here references the table rather than restating each comparison. The biomarker-precision result from Qian 2026 is direct, while the Shahid 2025 estimates are pooled and heterogeneous.

Mechanistically, the Qian 2026 signal is consistent with enhanced LDL-C lowering when ezetimibe and atorvastatin are co-administered at fixed doses, a pharmacokinetic/combination effect on the sterol absorption and synthesis pathways. By contrast, Shahid 2025 sits one directness step further from the patient: it aggregates recurrent ischemic stroke incidence across multiple high-dose statin RCTs, and the spread of p-values reported in the source indicates that not every pooled contrast reaches conventional significance. The human RCT layer therefore speaks to lipid lowering with high signal-to-noise (Qian 2026), whereas the meta-analytic layer mixes positive and null contrasts on a hard clinical endpoint (Shahid 2025). Preclinical data are not represented in this outcome class within the corpus.

The picked thesis is consistent with this disposition — the synthesis surfaces context-dependent signals rather than a single dosing effect, and the boundary conditions for high-dose statin benefit on recurrent ischemic stroke remain to be established in the corpus. No single dose-response number generalizes across both studies, and the prose deliberately preserves the asymmetry.

### Immune and Inflammation Outcomes

Sabeel 2025 is a systematic review and meta-analysis of statin effects on inflammatory markers in adults with chronic diseases, pooling data across study designs to evaluate immune-modulatory activity (Sabeel 2025). These pooled estimates synthesize indirect evidence because no single enrolled clinical population is the primary unit of analysis, and the very high I² value of 98.3% signals substantial between-study heterogeneity that tempers the strength of any single point estimate (Sabeel 2025).

Complementing the pooled inflammatory-marker analysis, Magavern 2025 is a GWAS of CRP response to statins within the GIST consortium, examining genetic determinants of statin-induced CRP change in adults (Magavern 2025). Magavern 2025 frames APOE as a contributor to statin response while explicitly noting that the interaction analysis did not reach conventional significance, so the genetic-modifier finding remains suggestive rather than definitive (Magavern 2025).

The contrast between a positive pooled biomarker result and a null pharmacogenomic interaction is therefore a within-outcome disagreement on the granularity of the immune signal, not a contradiction on direction at the biomarker level.

The within-corpus tension between Sabeel 2025 and Magavern 2025 on immune outcomes is most accurately read as a level-of-evidence disagreement rather than a directional conflict (severity 4 in the cross-study disagreement map). The clinical RCT and observational-cohort evidence therefore point in the same direction on the question of whether statins shift inflammatory biomarkers, with disagreement confined to whether the magnitude of shift is genetically conditioned. Readers should weight the pooled biomarker result from Sabeel 2025 as the dominant immune-outcome signal in this corpus, given its larger evidence base relative to the single GWAS reported in Magavern 2025.

### Longevity Outcomes

The longevity outcome class is addressed by six curated evidence sources spanning systematic reviews with meta-analyses, observational cohorts, and a randomized protocol with embedded biomarker substudy, giving the synthesis both pooled and primary-investigation depth. Across this evidence base, follow-up durations, dosing regimens, and population clinical substrates vary substantially, which is a structural feature of the corpus rather than a defect of any single report.

Mechanistically, the longevity signal aligns with the anti-inflammatory, endothelial-stabilizing, and pleiotropic actions of statins that have been advanced in preclinical and translational work, with the magnitude and statistical robustness of the human signal varying by clinical substrate.

In the cancer-prognosis literature, Vahed 2026 provides pooled observational evidence consistent with a survival benefit, while Hannachi 2026 demonstrates an analogous benefit in the high-acidity, high-inflammatory milieu of infective endocarditis, and Philippou 2025 reports direction-positive cohort data in sepsis despite a non-significant pooled RCT estimate.

The study design was retrospective and therefore indirect with respect to a healthy-aging longevity claim, but it provides one of the larger human cohorts with mortality follow-up in the corpus.

Effect direction in the source is recorded as unclear, reflecting a mixed p-value profile rather than a uniform positive or null finding.

### Muscle Function Outcomes

The sole muscle function entry in the curated corpus is a clinical RCT protocol (Sommariva 2025) designed to evaluate statin therapy in arrhythmogenic cardiomyopathy rather than in a healthy-aging population. The trial plans to enroll 102 patients meeting ACM diagnostic criteria and randomize them 1:1 to atorvastatin 80 mg/die or placebo for 18 months. As a protocol-stage document, the source carries no p-values or effect estimates; it is categorized as protocol-directness evidence anchored to a mechanistic human endpoint. The endpoint strategy and dose mirror the upper end of the LDL-lowering statin range used in cardiology outcome trials, allowing downstream linkage to lipid-pathway surrogates.

No on-treatment effect estimates can be cited because the trial is prospective and has not yet reported outcomes. Accordingly, this subsection cannot contribute a numeric efficacy claim to the synthesis, and any downstream statement about muscle function effects in this corpus must remain qualitative until results are posted.

Mechanistically, the muscle function outcome class sits at the intersection of statin pleiotropy (membrane stabilization, mitochondrial respiration) and a cardiac-specific disease substrate (arrhythmogenic cardiomyopathy), so any positive signal would not be generalizable to a sarcopenia or frailty phenotype. Within-corpus tensions for muscle function are not represented in the cross-study disagreement map because no non-orthogonal pairs share this outcome class, leaving the source to stand as a single anchor. By contrast, the broader longevity and comorbidity outcome classes carry multiple entries, and the muscle function signal here should be interpreted as a disease-modification probe rather than a generalized anti-aging endpoint.

Within-corpus alignment for muscle function is therefore narrow: Sommariva 2025 is the only muscle function source and it is a protocol, so no within-class disagreement can be characterized. Where cross-class comparison is informative, the mechanistic substrate underlying this functional endpoint overlaps with the longevity and safety comorbidity pathways reviewed elsewhere in this synthesis, but those overlaps are not adjudicable from a single protocol source. The standing recommendation is to treat Sommariva 2025 as a pending source of evidence rather than as a current answer to whether statins modulate muscle function in the context of healthy aging.

### Safety Outcomes

The corpus contains a single direct safety-oriented source, Zhang 2025, which is positioned as a network meta-analysis of lipid-lowering monotherapies and combinations (statins, ezetimibe, fibrates) restricted to published randomized controlled trials enrolling patients of any ethnicity and either gender (Zhang 2025). Because the source is tagged as a review-grade synthesis rather than a primary clinical RCT, its safety contribution is contextual and indirect: it aggregates tolerability signals across the broader lipid-lowering literature rather than reporting new incident adverse-event counts for a statins-for-longevity cohort. The source carries no p-values and no effect direction, which is consistent with the integrating thesis that null findings dominate the safety comorbidity space in this corpus. The lack of an enrolled clinical population or canonical trial identifier further indicates that safety conclusions for a longevity indication cannot be transported verbatim from this pooled lipid-lowering review.

Quantitatively, the only safety-class source (Zhang 2025) reports no extractable effect sizes, hazard ratios, odds ratios, or p-values, and the population field is explicitly marked as not applicable given the review-level scope. This absence is itself the salient numeric pattern: across the safety outcome class, the corpus provides zero reportable adverse-event numerics on statins used in longevity contexts, and zero direct safety endpoints anchored to a primary trial. Readers should therefore treat the safety evidence base as descriptive of lipid-lowering therapy in general, not as a quantified safety profile for statin use in healthy longevity-seeking adults.

Mechanistically, the safety profile of statins in a longevity context would be expected to depend on the same pleiotropic pathways invoked for cardiovascular benefit, but Zhang 2025 does not stratify adverse events by indication and therefore cannot discriminate longevity-context from dyslipidemia-context exposure. The review-level design means mechanistic interpretation is downstream rather than primary: Zhang 2025 aggregates trials whose endpoints are lipid reduction and cardiovascular events, with safety captured as incident adverse-event reporting rather than as a targeted mechanistic readout. Preclinical and mechanistic human studies relevant to statin safety in non-dyslipidemia populations are not represented in the safety outcome class, leaving the mechanism of any longevity-context safety signal unaddressed in the curated corpus. The clinical RCT substrate for safety in longevity use is, in effect, absent rather than negative.

Because the safety outcome class contains only a single source and the cross-study disagreement map records no same-outcome non-orthogonal pairs, there are no within-corpus safety tensions to adjudicate in this subsection. The integrating thesis nonetheless frames safety comorbidity as a null-dominated domain, and Zhang 2025 is the sole source bearing on that claim, providing no countervailing safety signal and no contradictory adverse-event findings. Any apparent contradiction between mechanistic plausibility of statin off-target effects and reassuring lipid-trial safety experience is not surfaced within the curated corpus and must therefore be treated as an external consideration rather than a within-corpus disagreement. The boundary condition for this subsection is therefore explicit: the curated corpus does not yet support a positive or negative safety verdict on statins for longevity, and Zhang 2025 stands as the only contextual anchor.

### Safety and Comorbidity Outcomes

Five curated sources contribute to the safety and comorbidity outcome class, spanning one direct randomized trial and four review-level syntheses. Fernando 2025 is a single-centre, human RCT protocol in a Sri Lankan cohort with acute coronary syndrome, comparing 40 mg versus 80 mg atorvastatin on efficacy, safety, and cost-effectiveness endpoints, with reported p-values of P = 0.118 and P = 0.045 across the protocol's pre-specified contrasts. The remaining four studies (Li 2025, Xu 2025, Cao 2025, and Zeng 2024) are review-level evidence — meta-analytic or systematic — in which safety and comorbidity findings are aggregated across multiple primary trials rather than generated de novo. No preclinical or animal safety studies were included in the curated corpus, so the safety narrative is anchored entirely in human evidence, and the evidence synthesis (Per-Study Endpoint Evidence) carries the full study-by-p-value mapping for this outcome class.

Across the review-level evidence, the quantitative picture is dominated by null comparisons and effect sizes that do not consistently favour one statin, dose, or combination over another. No pooled hazard ratio, odds ratio, or risk ratio is added beyond those present in the source sources.

Mechanistically, the safety and comorbidity evidence divides into two human-readable layers. The mechanistic and indirect human-evidence layer is represented by Li 2025, Xu 2025, Cao 2025, and Zeng 2024, which aggregate primary trials on statin class effects (Li 2025), statin effects in comorbid pulmonary disease (Xu 2025), statin-plus-PCSK9 combination outcomes after PCI (Cao 2025), and the broader landscape of statin adverse reaction mechanisms (Zeng 2024). Because Fernando 2025 is the only direct, prospectively randomized source in the corpus, the mechanistic substrate for safety signals beyond efficacy and myalgia rests on these aggregated syntheses, and any inference about longevity-relevant safety must traverse that indirect chain.

Within-corpus tensions on safety and comorbidity are most apparent between the single direct RCT and the four review-level sources. Fernando 2025 is a direct comparison in an enrolled clinical population, while Li 2025, Xu 2025, Cao 2025, and Zeng 2024 are reviews that pool heterogeneous primary studies, and the integrating thesis explicitly notes that null findings dominate the safety comorbidity class. The effect direction is reported as null in Li 2025, Cao 2025, and Zeng 2024, unclear in Fernando 2025 and Xu 2025, and the cross-study disagreement map flags four indirectness gaps pairing Fernando 2025 with each of the reviews on the same outcome class. These contrasts frame the safety comorbidity class as a mixed picture in which the direct evidence remains thin and the indirect syntheses diverge in their effect directions, consistent with the brief's characterization of the statins–longevity case as incomplete.

### Skeletal, Fracture, and Bone Outcomes

A single curated review, Yoshida 2026, addressed adjunctive locally delivered statins in periodontal therapy and pre-implant bone regeneration, framing the bone endpoint as a review-level synthesis rather than a primary clinical trial. The source pooled mean differences across included studies, with statistical significance reported as P < 0.0001 in the underlying meta-analytic comparisons. Because the source is a review and not a direct fracture-endpoint RCT, the relevance to systemic skeletal fracture in the statins-longevity frame is indirect. The direction of effect is not coded in the source (effect direction: null), consistent with a heterogeneous body of local dental-bone outcomes rather than a unidirectional systemic bone effect.

The quantitative anchor is the pooled significance reported in Yoshida 2026 (P < 0.0001), which reflects combined effects across the included periodontal and peri-implant trials rather than a single dose-response or fracture-incidence estimate. The review does not enumerate a single canonical trial, and the source's effect direction field is null, so no specific effect size, hazard ratio, or odds ratio can be reported from the source for systemic fracture risk. Per the evidence synthesis's per-study endpoint evidence, this entry is a single-row evidence layer rather than a meta-analytic pivot point for the longevity question. Consequently, the section's quantitative claim is limited to the reported pooled significance rather than to any absolute risk reduction or fracture-incidence figure.

Mechanistically, locally delivered statins in periodontal and peri-implant bone healing models a tissue-regenerative pathway — osteoblast stimulation and anti-resorptive effects at the bone interface — rather than a systemic anti-aging mechanism. The source's design label (observational cohort) coexists with a review-level synthesis, indicating the underlying primary studies are largely non-randomized local-application reports. This means the mechanistic substrate is best characterized as preclinical and small-clinical local-bone regeneration evidence, not as a longevity-grade systemic skeletal endpoint. As such, Yoshida 2026 informs biological plausibility at the tissue level but does not anchor a systemic fracture-prevention claim in the statins-longevity frame.

Within-corpus tensions for the skeletal/bone outcome class are minimal because the cross-study disagreement map contains no same-outcome non-orthogonal pairs that engage this source. The review therefore stands as an isolated evidence layer rather than as one pole of an internal disagreement. The picked thesis characterizes the broader statins-longevity case as incomplete, with mechanistic plausibility coexisting with mixed or sparse human-RCT evidence; Yoshida 2026 illustrates the mechanistic-plausibility side of that characterization for bone specifically, while leaving the systemic fracture-incidence question open. No opposing source within this outcome class was identified to contest the P < 0.0001 pooled significance.

### Mortality and Survival Outcomes

This positions the Ch 2025 evidence as hypothesis-generating rather than confirmatory for any statin–longevity link in non-surgical populations.

The clustering of p-values below 0.05 for the majority of contrasts is consistent with an effect on hard cardiovascular endpoints in the post-CABG setting, while the two non-significant values flag endpoints or subgroups where the survival advantage did not reach statistical significance. Per the source, the overall effect direction remains coded as unclear because the favorable contrasts are not unanimous across all reported comparisons. Zhou 2026 contributes a parallel null finding in a different mortality context: in a meta-analysis of statin use and amyotrophic lateral sclerosis survival, the pooled estimate was Log(HR) = -0.04 with P = 0.597, indicating no detectable association between statin exposure and ALS survival.

Mechanistically, the Ch 2025 post-CABG signal maps onto the canonical pleiotropic statin pathway — LDL lowering, plaque stabilization, and anti-inflammatory effects on the vascular endothelium — which would plausibly translate into reduced post-operative cardiovascular mortality. By contrast, the Zhou 2026 ALS-survival null finding suggests that in neurodegenerative disease, where the mechanistic substrate is neuronal rather than vascular, statin exposure does not move the survival endpoint in either direction. Preclinical data on statin effects in motor-neuron models are not represented in the sources, so the null human result cannot be cross-referenced to a mechanism class within this corpus. Together these two source-level observations frame mortality effects as indication-dependent rather than universal.

Ch 2025 operates in a secondary-prevention cardiovascular population at high absolute risk, where any mortality delta is easier to detect, while Zhou 2026 addresses a rare neurodegenerative condition with a different causal pathway and lower event rates. The disagreement is therefore most parsimoniously read as a population-and-indication effect rather than a true conflict in the underlying biology. For the Statins thesis, the takeaway is that survival signals in the corpus are anchored to vascular and post-surgical contexts rather than to healthy-aging longevity writ large, and the boundary conditions for generalization remain to be established.

Mortality and Survival remains a separate Results slice (n=2; claims=66; unclear signal in 1/2 sources; 1 indirect; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.

## Cross-Domain Synthesis

The first and most consequential cross-outcome tension is whether the mechanistic and immunomodulatory signals attributed to statins can be reconciled with the mixed or null human-RCT evidence on hard longevity endpoints. The mechanism that Sabeel 2025 documents is real at the molecular level, but the boundary condition that would make it matter for hard outcomes — sustained suppression of inflammation in populations with high baseline inflammatory burden and a follow-up window long enough to translate cytokine reduction into survival — has not been demonstrated. Until a trial powered on mortality in an inflammation-selected population closes, the surrogate-endpoint caution articulated by Ioannidis 2005 should govern interpretation, and the mechanistic plausibility must be reported as plausibility, not as evidence of longevity benefit.

A second load-bearing tension is the conflict between the direct dosing/clinical RCT literature and the indirect or pooled estimates of functional decline and physical performance in older adults. The cross-domain tension is that an effective LDL-lowering drug with strong RCT evidence for cardiovascular protection is also producing a measurable functional signal in the population least equipped to absorb it. The boundary condition that adjudicates this is duration: a short-horizon lipid trial cannot detect a slowly accruing muscle-function or gait-speed decrement, and a long-horizon geriatric cohort study cannot isolate statin effects from comorbidity and polypharmacy. The STREAM Trial Biomarker 2026 protocol, which randomizes multimorbid adults aged 70+ on primary-prevention statins to continuation versus discontinuation with a composite major-CV endpoint, is the design most likely to adjudicate the question, but it has not yet reported. Until it does, the proper synthesis is that statins’ lipid and cardiovascular efficacy is well established in direct RCTs while the older-adult functional cost is supported by indirect cohort evidence, and the two should not be averaged into a single net-benefit estimate.

 The Makhlouf migraine signal is biologically plausible because HMGCR inhibition modulates endothelial and inflammatory pathways implicated in migraine, and the Mendelian randomization design reduces confounding, but the Du 2025 and Veillette 2025 null findings on neurodegeneration, which are powered by vastly larger pooled samples, suggest that the pleiotropic benefits do not extend uniformly across the central nervous system. The boundary condition that may explain the divergence is indication: migraine is a vascular-inflammation phenotype that responds to endothelial stabilization, whereas late-life dementia and post-traumatic neurodegeneration are dominated by protein-misfolding and structural injury pathways that statins do not modify. The evidence that would resolve this is a head-to-head RCT comparing statins in migraine-enriched versus dementia-enriched cohorts with primary endpoints on each respective phenotype, not the cross-purpose pooling that the current literature forces. Until such a trial exists, the synthesis is that the contextual other outcome class is heterogeneous rather than uniformly positive, and the Makhlouf 2025 effect should not be generalized to neuroprotection.

Another tension concerns safety comorbidity outcomes, where the direct clinical RCT evidence (Fernando 2025, Qian 2026, Zheng 2025) suggests manageable or no excess risk at the doses and durations studied, yet pooled meta-analytic evidence (Li 2025, Xu 2025, Cao 2025) finds either null differences in adverse-event incidence or modest safety signals that depend heavily on the comparator and population. The tension is that direct RCTs minimize the apparent safety burden through selection and short follow-up, while the broader meta-analytic record suggests the safety profile is dose-, drug-, and population-dependent rather than flat. Until the STREAM non-inferiority discontinuation trial reports, safety claims in older adults should be hedged.

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

Cross-domain interpretation compares outcome classes and identifies where signals converge or diverge. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation
separates direct clinical findings from mechanistic and adjacent evidence,
preserving uncertainty where endpoint, population, comparator, or follow-up
differs. This conservative boundary keeps the scientific question visible
without inserting unsupported numeric detail or stronger causal language than
the retained evidence allows. Where studies point in different directions,
the synthesis treats that disagreement as information about design and
applicability rather than as noise. The key question becomes which population,
intervention schedule, comparator, and endpoint layer would be required for the
claim to survive a prospective test. This preserves the practical implication
for readers: favorable signals can justify targeted follow-up, while unresolved
tradeoffs still limit broad clinical or public-health recommendations.


### Load-Bearing Tensions

Each tension below is load-bearing: it changes whether the outcome is read as a robust class effect or as design-contingent evidence. Numeric anchors remain in the structured evidence tables rather than in this interpretive list.

- Makhlouf 2025 versus Markan 2025: a Contextual Adjacent Evidence null vs positive tension. Leading explanations: Effect is endpoint-distance dependent: positive at proximal endpoints, null at distal endpoints; Effect is population-stratified: detectable only in subgroups with elevated baseline pathway activity.
- Sabeel 2025 versus Magavern 2025: a Immune and Inflammation null vs positive tension. Leading explanations: Effect is endpoint-distance dependent: positive at proximal endpoints, null at distal endpoints; Effect is population-stratified: detectable only in subgroups with elevated baseline pathway activity.
- Lee 2025 versus Huang 2026: a Contextual Adjacent Evidence null vs positive tension. Leading explanations: Effect is endpoint-distance dependent: positive at proximal endpoints, null at distal endpoints; Effect is population-stratified: detectable only in subgroups with elevated baseline pathway activity.
- Philippou 2025 versus Markle 2026: a Longevity null vs positive tension. Leading explanations: Effect is endpoint-distance dependent: positive at proximal endpoints, null at distal endpoints; Effect is population-stratified: detectable only in subgroups with elevated baseline pathway activity.
- Alqasrawi 2025 versus Fernando 2025: a Cardiometabolic mechanism vs clinical tension. Leading explanations: Population or dose-regime difference between the two studies modifies the effect; Endpoint-distance from pathway substrate explains the directional disagreement.## Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Across 53 curated reference papers, the evidence base for Statins shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Null findings dominate: contextual other, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 53 included sources. By directness, the breakdown is: review (n=28), indirect (n=18), protocol (n=4), direct (n=3). 41 of 53 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: older adults; type 2 diabetes patients; adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The most consequential limitation of this synthesis is the absence, in the curated corpus, of a long-term mortality RCT conducted in non-diabetic, primary-prevention adults free of established cardiovascular disease at enrollment. The indirect evidence that is available — for example Hannachi 2026 reporting a follow-up mortality HR in infective endocarditis, or Vahed 2026 reporting a CRC all-cause mortality HR — comes from secondary-prevention or disease-specific populations and cannot be transported to the headline scenario without strong external validity assumptions. Generalization from these secondary-prevention cohorts to a healthy 55-year-old considering statin therapy for putative longevity benefit is unsupported by the evidence reviewed. Until a dedicated primary-prevention, non-diabetic mortality RCT appears in the corpus, the central claim of the synthesis must be qualified as biologically plausible but not empirically settled in the populations where the public-health message is most often delivered.

A fifth limitation is the mechanism-to-clinic gap. Where the corpus has mechanistic or biomarker-level evidence for a claim that is then transported to a clinical longevity conclusion, the bridge is not made within the sources themselves. Across these mechanistic-to-clinic bridges, the sources support plausibility, not proof, and the synthesis cannot substitute the former for the latter.

### Residual uncertainty

The main limitation is not only the size of the retained corpus, but
also the uneven directness of the evidence across outcome classes. Some findings are clinically proximate, some are mechanistic, and some
are indirect or model-system evidence. The paper therefore avoids
treating all sources as equivalent. Its conclusions are strongest
where directness, clinical directness, and source-context safety align,
and weaker where evidence must be translated across populations,
species, intervention schedules, or measurement systems.

## Conclusion

For Statins longevity, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

## What This Synthesis Adds

This synthesis maps 53 included sources on Statins Longevity across 10 outcome classes and 197 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 53 curated reference papers, the evidence base for Statins shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Null findings dominate: contextual other, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the null vs positive between Makhlouf 2025 and Du 2025 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Vahed 2026, Sabeel 2025, Makhlouf 2025, Masood 2026, Philippou 2025) emphasize convergent signals on Statins Longevity. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 7 | mixed, null, positive, unclear | conflict-resolution gap |
| cardiometabolic | 0 | 3 | mixed, unclear | direct interventional hard-endpoint gap |
| muscle function | 0 | 1 | null | direct interventional hard-endpoint gap |
| safety | 0 | 1 | null | direct interventional hard-endpoint gap |
| immune and inflammation | 0 | 2 | null, positive | conflict-resolution gap |
| mortality and survival | 0 | 2 | null, unclear | direct interventional hard-endpoint gap |
| skeletal, fracture, and bone | 0 | 1 | null | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 1 | 28 | mixed, null, positive, unclear | conflict-resolution gap |
| dosing and pharmacokinetics | 1 | 1 | null, unclear | replication gap |
| safety and comorbidity | 1 | 4 | null, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: conflict-resolution gap | 0 direct and 7 indirect sources; direction profile: mixed, null, positive, unclear |
| P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: mixed, unclear |
| P3 | muscle function: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |
| P4 | safety: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |
| P5 | immune and inflammation: conflict-resolution gap | 0 direct and 2 indirect sources; direction profile: null, positive |

### Next-Study Design Recommendation

The next high-yield study for Statins Longevity should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Qian 2026; tier=A1; directness=direct; endpoint=dosing pharmacokinetics; direction=null.
- Fernando 2025; tier=A1; directness=direct; endpoint=safety comorbidity; direction=unclear; representative statistic=P = 0.045.
- Zheng 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
- Vahed 2026; tier=B1; directness=review; endpoint=longevity; direction=mixed; representative statistic=P < 0.001.
- Sabeel 2025; tier=B1; directness=review; endpoint=immune; direction=positive; representative statistic=P < 0.001.
- Makhlouf 2025; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001.
- Masood 2026; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.00001.
- Philippou 2025; tier=B1; directness=review; endpoint=longevity; direction=positive; representative statistic=P < 0.00001.
- Shahid 2025; tier=B1; directness=review; endpoint=dosing pharmacokinetics; direction=unclear; representative statistic=P = 0.005.
- Hannachi 2026; tier=B1; directness=review; endpoint=longevity; direction=positive; representative statistic=P < 0.00001.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Additional corpus sources included animal/preclinical evidence; Qian 2026: outcome=dosing pharmacokinetics; directness=direct; tier=A1; direction=null; claims=75.
- Fernando 2025: outcome=safety comorbidity; directness=direct; tier=A1; direction=unclear; claims=36.
- Zheng 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=31.
- Vahed 2026: outcome=longevity; directness=review; tier=B1; direction=mixed; claims=271.
- Sabeel 2025: outcome=immune; directness=review; tier=B1; direction=positive; claims=130.
- Makhlouf 2025: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=positive; claims=100.
- Masood 2026: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=88.
- Philippou 2025: outcome=longevity; directness=review; tier=B1; direction=positive; claims=59.
- Shahid 2025: outcome=dosing pharmacokinetics; directness=review; tier=B1; direction=unclear; claims=55.
- Hannachi 2026: outcome=longevity; directness=review; tier=B1; direction=positive; claims=2.
- STREAM Trial Biomarker 2026: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=1.
- Alqasrawi 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=318.
- Novak 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=mixed; claims=210.
- Spiegeleer 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=194.
- Asiimwe 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=146.
- Li 2025: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=128.
- Markle 2026: outcome=longevity; directness=review; tier=B2; direction=null; claims=127.
- Khalil 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=124.
- Wong 2026: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=98.
- Xu 2025: outcome=safety comorbidity; directness=review; tier=B2; direction=unclear; claims=76.
- Cao 2025: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=75.
- Lee 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=65.
- Ch 2025: outcome=mortality survival; directness=indirect; tier=B2; direction=unclear; claims=58.
- Yoshida 2026: outcome=skeletal fracture bone; directness=review; tier=B2; direction=null; claims=58.
- Khalili 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=48.
- Tan 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=48.
- MORENO 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=47.
- Kakkar 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=35.
- Sole 2026: outcome=longevity; directness=indirect; tier=B2; direction=mixed; claims=35.
- Demirci 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=33.
- Schmidt 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=33.
- Ali 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=31.
- Du 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=29.
- Albawaneh 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=27.
- Huang 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=positive; claims=27.
- Zhang 2025: outcome=safety; directness=review; tier=B2; direction=null; claims=27.
- Li 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=25.
- Markan 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=23.
- Veillette 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=21.
- Xiang 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=20.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs positive: Makhlouf 2025 vs Du 2025; Makhlouf 2025 (positive on contextual other) vs Du 2025 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Makhlouf 2025 vs Veillette 2025; Makhlouf 2025 (positive on contextual other) vs Veillette 2025 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Makhlouf 2025 vs Xiang 2025; Makhlouf 2025 (positive on contextual other) vs Xiang 2025 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Makhlouf 2025 vs Aebi 2025; Makhlouf 2025 (positive on contextual other) vs Aebi 2025 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Makhlouf 2025 vs Markan 2025; Makhlouf 2025 (positive on contextual other) vs Markan 2025 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Makhlouf 2025 vs Kolimas 2025; Makhlouf 2025 (positive on contextual other) vs Kolimas 2025 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Makhlouf 2025 vs Khalili 2025; Makhlouf 2025 (positive on contextual other) vs Khalili 2025 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Makhlouf 2025 vs Lee 2025; Makhlouf 2025 (positive on contextual other) vs Lee 2025 (null on contextual other) — partial conflict

## References

- **Alqasrawi 2025.** _Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE’s multiethnic population._ Human Genomics, 2025. DOI: 10.1186/s40246-025-00753-6. PMID: 40281622.
- **Vahed 2026.** _The impact of statin use on colorectal cancer prognosis: a systematic review and meta-analysis._ BMC Gastroenterology, 2026. DOI: 10.1186/s12876-025-04398-6. PMID: 41663946.
- **Novak 2026.** _Alzheimer's disease in patients prescribed statins: A real-world data analysis of U.S. patient health records._ Journal of Alzheimer's Disease, 2026. DOI: 10.1177/13872877261424220. PMID: 41761642.
- **Spiegeleer 2025.** _The association between statins and gait speed reserve in older adults: effects of concomitant medication._ GeroScience, 2025. DOI: 10.1007/s11357-025-01682-x. PMID: 40332452.
- **Asiimwe 2026.** _APOE genotype and the effect of statins on lipid outcomes: A meta‐analysis._ British Journal of Clinical Pharmacology, 2026. DOI: 10.1002/bcp.70493. PMID: 41702864.
- **Sabeel 2025.** _Impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases: A systematic review and meta-analysis._ PLOS One, 2025. DOI: 10.1371/journal.pone.0323749. PMID: 40440323.
- **Li 2025.** _A Meta-Analysis of the Incidence of Adverse Reactions of Statins in Various Diseases._ Cardiovascular Therapeutics, 2025. DOI: 10.1155/cdr/6684099. PMID: 40529509.
- **Markle 2026.** _Pre-morbid statin use and mortality in trauma: a systematic review and meta-analysis._ Langenbeck's Archives of Surgery, 2026. DOI: 10.1007/s00423-026-04011-8. PMID: 41925893.
- **Khalil 2025.** _Comparative Effectiveness of Cholesteryl Ester Transfer Protein (CETP) Inhibitors on Lipid Profiles in Adults With Hyperlipidemia: A Comprehensive Systematic Review and Frequentist Network Meta‐Analysis of Randomized Controlled Trials._ Clinical Cardiology, 2025. DOI: 10.1002/clc.70204. PMID: 40947782.
- **Makhlouf 2025.** _Exploring the association between statins use or HMG-CoA reductase inhibition and migraine: a systematic review and meta-analysis._ The Journal of Headache and Pain, 2025. DOI: 10.1186/s10194-025-01957-w. PMID: 39901103.
- **Wong 2026.** _Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation._ eClinicalMedicine, 2026. DOI: 10.1016/j.eclinm.2026.103798. PMID: 41732195.
- **Masood 2026.** _Pemafibrate for hypertriglyceridemia: a meta-analysis of randomized controlled trials evaluating efficacy and safety outcomes._ Systematic Reviews, 2026. DOI: 10.1186/s13643-026-03186-x. PMID: 42010647.
- **Xu 2025.** _Comparative effectiveness of statins for chronic obstructive pulmonary disease patients with pulmonary hypertension: systematic review and network meta-analysis._ Frontiers in Medicine, 2025. DOI: 10.3389/fmed.2025.1640270. PMID: 40963565.
- **Cao 2025.** _Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis._ Frontiers in Cardiovascular Medicine, 2025. DOI: 10.3389/fcvm.2025.1612095. PMID: 41235335.
- **Qian 2026.** _LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial._ Advances in Therapy, 2026. DOI: 10.1007/s12325-025-03429-8. PMID: 41553712.
- **Lee 2025.** _Prognostic Implication of LDL-C Variability and Its Association with Lipid-Lowering Strategies: Insights from the RACING and LODESTAR Trials._ Yonsei Medical Journal, 2025. DOI: 10.3349/ymj.2024.0476. PMID: 40873140.
- **Philippou 2025.** _The Impact of Statin Use on Sepsis Mortality: A Systematic Review and Meta-Analysis._ Medicina, 2025. DOI: 10.3390/medicina61091563. PMID: 41010954.
- **Ch 2025.** _Effect of Statin Intensity on Cardiovascular Outcomes and Survival Following Coronary Artery Bypass Grafting._ Clinical Cardiology, 2025. DOI: 10.1002/clc.70170. PMID: 40590628.
- **Yoshida 2026.** _Adjunctive Use of Locally Delivered Statins in Periodontal Therapy and Pre‐Implant Bone Regeneration: A Systematic Review and Meta‐Analysis._ Clinical and Experimental Dental Research, 2026. DOI: 10.1002/cre2.70364. PMID: 42046838.
- **Shahid 2025.** _High-dose statins for the prevention of recurrent ischemic stroke: a systematic review and meta-analysis of randomized controlled trials._ Annals of Saudi Medicine, 2025. DOI: 10.5144/0256-4947.2025.112. PMID: 40189852.
- **Khalili 2025.** _The role of statins during pregnancy on maternal risk of preeclampsia: a systematic review and meta-analysis._ BMC Pregnancy and Childbirth, 2025. DOI: 10.1186/s12884-025-07967-5. PMID: 40796817.
- **Tan 2025.** _Exploring the relationship between atorvastatin and rosuvastatin use and respiratory, thoracic, and mediastinal disorders: A retrospective study._ Medicine, 2025. DOI: 10.1097/MD.0000000000044984. PMID: 41088630.
- **MORENO 2026.** _ROLE OF STATINS IN CIRRHOTIC PORTAL HYPERTENSION: META-ANALYSIS OF RANDOMIZED STUDIES._ Arquivos de Gastroenterologia, 2026. DOI: 10.1590/S0004-2803.24612025-036. PMID: 42154843.
- **Fernando 2025.** _Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial._ Trials, 2025. DOI: 10.1186/s13063-025-08943-2. PMID: 40890828.
- **Sole 2026.** _Myasthenia Gravis Outcomes After Use of Statins and Other Contraindicated Treatments: Results From the French National Insurance Database._ European Journal of Neurology, 2026. DOI: 10.1111/ene.70504. PMID: 41574649.
- **Kakkar 2026.** _Effect of lifestyle modification and atorvastatin on dyslipidemia and endothelial dysfunction markers in children with steroid resistant nephrotic syndrome._ Jornal Brasileiro de Nefrologia, 2026. DOI: 10.1590/2175-8239-JBN-2025-0212en. PMID: 42060385.
- **Demirci 2025.** _The role of statins in modulating subclinical inflammatory markers in coronary slow flow phenomenon._ Medicine, 2025. DOI: 10.1097/MD.0000000000043940. PMID: 40797397.
- **Schmidt 2026.** _Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins._ Circulation. Genomic and Precision Medicine, 2026. DOI: 10.1161/CIRCGEN.125.005345. PMID: 41664920.
- **Aebi 2025.** _Rationale and design of ‘discontinuing statins in multimorbid older adults without cardiovascular disease (STREAM)’: study protocol of a randomised non-inferiority clinical trial._ BMJ Open, 2025. DOI: 10.1136/bmjopen-2024-093833. PMID: 40409969.
- **Zheng 2025.** _Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis._ Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2025. DOI: 10.1161/JAHA.125.042112. PMID: 40970544.
- **Ali 2026.** _Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo._ Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2026. DOI: 10.1161/JAHA.125.046943. PMID: 41608890.
- **Du 2025.** _The role of statins in dementia or Alzheimer’s disease incidence: a systematic review and meta-analysis of cohort studies._ Frontiers in Pharmacology, 2025. DOI: 10.3389/fphar.2025.1473796. PMID: 39963242.
- **Zhang 2025.** _Efficacy and safety of statins, ezetimibe, and fibrates monotherapy or combination therapy for hyperlipidemia: a systematic review and network meta-analysis._ European Journal of Medical Research, 2025. DOI: 10.1186/s40001-025-02805-y. PMID: 40551216.
- **Albawaneh 2025.** _Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis._ Annals of Medicine, 2025. DOI: 10.1080/07853890.2025.2594355. PMID: 41320800.
- **Huang 2026.** _Clinical efficacy of combining fenofibrate with statins in patients with diabetes and hyperlipidemia: a meta-analysis._ Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1694928. PMID: 41958876.
- **Park 2025.** _Effect of atorvastatin versus no S tatin T reatment on major clinical events in A cute C ardio E mbolic stroke patients without a definite indication for statin therapy: protocol for the STACE trial._ Trials, 2025. DOI: 10.1186/s13063-025-09097-x. PMID: 41013792.
- **Li 2026.** _Prognostic role of statins in colorectal cancer: a systematic review and meta-analysis._ Frontiers in Oncology, 2026. DOI: 10.3389/fonc.2026.1763323. PMID: 41930205.
- **Markan 2025.** _Assessing the Role of Statins as an Adjunctive Anti-VEGF Therapy for Clinically Significant Macular Edema (CSME) in Type 2 Diabetes Mellitus._ Romanian Journal of Ophthalmology, 2025. DOI: 10.22336/rjo.2025.35. PMID: 40698099.
- **Veillette 2025.** _Effect of statins on neurological functional outcomes in critically ill adult patients with traumatic brain injury: a systematic review and meta-analysis._ BMJ Open, 2025. DOI: 10.1136/bmjopen-2024-091971. PMID: 39971597.
- **Xiang 2025.** _Lipid-lowering effect of combined therapy with high-intensity statins and CETP inhibitors: a Systematic Review and meta-analysis._ Frontiers in Endocrinology, 2025. DOI: 10.3389/fendo.2025.1512670. PMID: 40375946.
- **Takechi 2025.** _Effectiveness of Statins for Oxaliplatin‐Induced Peripheral Neuropathy: A Multicenter Retrospective Observational Study._ Clinical and Translational Science, 2025. DOI: 10.1111/cts.70318. PMID: 41021349.
- **Pintea 2026.** _The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review._ Frontiers in Pharmacology, 2026. DOI: 10.3389/fphar.2026.1815366. PMID: 42147338.
- **Voit 2026.** _Pragmatic trial assessing polygenic risk driven statin therapy for cardiovascular disease prevention: study protocol for the EE-PRS trial._ BMJ Open, 2026. DOI: 10.1136/bmjopen-2026-120048. PMID: 42203295.
- **Kolimas 2025.** _Slowing Thoracic Aortic Aneurysm Growth with Statins: A Meta-Analysis._ Current Cardiology Reviews, 2025. DOI: 10.2174/011573403X343512250127075044. PMID: 39949099.
- **Vordenberg 2026.** _Trust first, concerns second: An international vignette study of older adults' preferences towards deprescribing statins._ British Journal of Clinical Pharmacology, 2026. DOI: 10.1002/bcp.70440. PMID: 41531191.
- **Sommariva 2025.** _Statin effect on arrhythmogenic cardiomyopathy disease progression (SEARCH): Randomized clinical study protocol._ PLOS One, 2025. DOI: 10.1371/journal.pone.0332876. PMID: 41021550.
- **Saishoji 2025.** _HMG‐CoA reductase inhibitors (statins) versus placebo for people with schizophrenia._ The Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD014565. PMID: 40970410.
- **Magavern 2025.** _GWAS of CRP response to statins further supports the role of APOE in statin response: A GIST consortium study._ Pharmacological research, 2025. DOI: 10.1016/j.phrs.2024.107575. PMID: 39798939.
- **Lv 2025.** _Preclinical efficacy and mechanisms of statin-loaded polymeric nanocapsules: a meta-analysis of tumor lipid metabolism inhibition._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-22302-w. PMID: 41184536.
- **Zhou 2026.** _The effect of statins on the survival of patients with amyotrophic lateral sclerosis: a meta-analysis._ Frontiers in Neurology, 2026. DOI: 10.3389/fneur.2026.1753992. PMID: 41993642.
- **Zeng 2024.** _Advances in statin adverse reactions and the potential mechanisms: A systematic review._ Journal of Advanced Research, 2024. DOI: 10.1016/j.jare.2024.12.020. PMID: 39681285.
- **Hannachi 2026.** _The Potential Role of Statins in Infective Endocarditis: A Meta-Analysis._ Curr Vasc Pharmacol, 2026. DOI: 10.2174/0115701611419387251202152013. PMID: 41926297.
- **STREAM Trial Biomarker 2026.** _STREAM Trial - Biomarker._ 2026. Identifier unavailable; no DOI or PMID in source metadata.

### Background References

*Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*

- **Studenski 2011.** _Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58._ DOI: 10.1001/jama.2010.1923. PMID: 21205966.
- **Bohannon 1997.** _Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26(1):15-19._ DOI: 10.1093/ageing/26.1.15.
- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.

{
  "article_type": "evidence_map",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "30b8af18-f881-419d-86bc-5f8a1f4425b1",
  "title": "Hypothesis-Generating Brief: Statins longevity \u2014 full paper"
}